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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the diagnostic accuracy of total serum bile acids or total serum bile acids profile, or both for the diagnosis of intrahepatic
cholestasis of pregnancy in pregnant women presenting with pruritus.
To compare the diagnostic accuracy of total serum bile acids and each component of serum bile acid profile, considered independently
or in combination, in diagnosing intrahepatic cholestasis of pregnancy; to define the optimal cut-off values for these; and to investigate
possible sources of heterogeneity.
B A C K G R O U N D
Intrahepatic cholestasis of pregnancy (also known as obstetric
cholestasis) is a pregnancy-specific liver disorder, that is possibly
associated with an increased risk of severe fetal adverse events.
Intrahepatic cholestasis of pregnancy was first described in 1883
(Ahlfeld 1883), andmany other publications have followed. How-
ever, our knowledge of the disease is still incomplete (Reyes 1997;
Sinakos 2010).
The prevalence of intrahepatic cholestasis of pregnancy varies ac-
cording to geographical location and ethnicity, as genetic and en-
vironmental factors play a role in its manifestation (Geenes 2009).
The range of intrahepatic cholestasis of pregnancy has been calcu-
lated to be between 0.01% and 0.1% in North America, South-
ern Europe, Asia, and Australia (Reyes 1997); between 1.5% and
4.0% in South America (Reyes 1997); and 1.5% in Scandinavia
(Glantz 2004). Among the most affected countries in the world
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are Chile, Bolivia, Finland, Sweden, and Portugal (Geenes 2009).
Most often the disease affects women with a history of intrahepatic
cholestasis during previous pregnancies (Reyes 1997), history of
cholestasis associated with the use of oral contraceptives (Pathak
2010), family or personal history of biliary disease (Diken 2014),
hepatitis C viral infection (Paternoster 2002), twin pregnancies
(Gonzalez 1989), or in vitro fertilisation pregnancies (Koivurova
2002). It is also suggested that the risk of acquiring intrahepatic
cholestasis of pregnancy is higher in women over the age of 35
years (Heinonen 1999).
There are multiple factors involved in the aetiopathogenesis of
intrahepatic cholestasis of pregnancy. Among the genetic factors
suspected in causing the disease are mutations in genes that en-
code biliary transport proteins (Dixon 2014), or mutations in bile
acid receptors (such as farnesoid X receptor (Jacquemin 1999)).
Likewise, among factors suspected in causing the disease are sea-
sonal variations (with higher prevalences reported in winter (Brites
1998a)), low selenium intake, erucic acid, increased gut absorption
of bacterial endotoxins, pollutants (such as pesticides), infections,
or drugs (Geenes 2009;Diken 2014;Ozkan 2015).Hormonal fac-
tors such as oestrogens, progesterone, or their metabolites can also
play a role in its development (Reyes 2008; Abu-Hayyeh 2013).
Seasonal variations and an increase in dietary selenium intake may
have played a role in the decrease of the prevalence of the disease
observed in Chile and Scandinavia since the late 1980s’ (Kauppila
1987; Reyes 2000a). Probably owing to these variations, the preva-
lence of intrahepatic cholestasis of pregnancy in Chile decreased
from a range of 11.8% to 27.7% during the 1970s (the higher
value observed for Araucanian ethnicity) (Reyes 1978) to themost
recently reported range of 1.5% to 4.0% in the 1990s (Reyes
1997).
Some studies showed an association between intrahepatic cholesta-
sis of pregnancy and metabolic abnormalities in affected pregnant
women, such as impaired glucose tolerance, hyperinsulinaemia,
or dyslipidaemia (Martineau 2015), which may lead to increased
fetal growth and sex-specific increased susceptibility to an obese,
diabetic phenotype of the offspring (Desai 2013; Papacleovoulou
2013).
In clinical practice, presence of pruritus from the last third of
pregnancy and the ’otherwise unexplained’ abnormalities in the
most common liver tests, seems enough to support the diagnosis
of intrahepatic cholestasis of pregnancy (Green-top Guideline
no.43). However, owing to the non-specific features of the disease,
the mandatory exclusion of all other possible underlying diseases
is not always easy and to ascertain the right diagnosis may not
be possible until a certain time point after the delivery, when the
spontaneous relief of pruritus and normalisation of liver test values
occur (Beuers 2006).
The pathophysiology of intrahepatic cholestasis of pregnancy is
still poorly understood. An increase in bile acid serum concentra-
tion is thought to play a primary role in the onset of the typical
cholestatic pruritus (Pathak 2010); however, a correlation between
the bile acid serum concentration and severity of pruritus has not
been demonstrated. Moreover, the increased passage of bile acids
through the placental barrier appears to be toxic for the fetus dur-
ing intrahepatic cholestasis of pregnancy (Perez 2005; Sheik Abdul
Kadir 2010). Therapies so far have been empirical, and they all
aimed at reducing maternal symptoms, improving results of liver
tests, and reducing total bile acid concentration. Ursodeoxycholic
acid (UDCA), S-adenosylmethionine (SAMe), dexamethasone, or
cholestyramine as well as vitamin K (aiming at preventing possible
postpartum bleeding) are the most used therapies (Ozkan 2015).
To try to reduce the risk of stillbirth, which seems to occur most
often in the last weeks of pregnancy (Puljic 2015), most clinicians
choose an early delivery of the baby because of the medical con-
dition of the mother, usually at week 37. Whether the increased
preterm birth rate associated with intrahepatic cholestasis of preg-
nancy is due to the disease itself or to its active management is still
uncertain (Henderson 2014).
One Cochrane Review on interventions for treating cholestasis in
pregnancy concluded that there was no evidence to recommend
early-term delivery and that there was insufficient evidence to sup-
port the use of SAMe, guar gum, activated charcoal, dexametha-
sone, cholestyramine, yinchenghao decoction, danxiaoling pill, yi-
ganling, alone, or in combination (Gurung 2013). However, the
review found that UDCA seemed to improve the maternal symp-
tom of pruritus (Gurung 2013), which agrees with the result of
a meta-analysis by Bacq and colleagues published in 2012 (Bacq
2012). In addition, the meta-analysis by Bacq strongly suggested
that UDCA was also beneficial for the fetal outcome (Bacq 2012);
however, the Cochrane Review did not reach this conclusion as
the evidence was insufficient (Gurung 2013).
Total serumbile acids (TSBA), alone or in combinationwith serum
aminotransferases, are the most often used biomarkers for intra-
hepatic cholestasis of pregnancy in clinical practice. Some com-
ponents of the serum bile acid profile, especially primary bile acid
concentrations (Sjövall 1966; Laatikainen 1977;Heikkinen 1983)
or total concentration of tauro-conjugated (T-c) forms (Tribe
2010), may provide more specific information than TSBAs when
diagnosing the disease, defining its severity, and monitoring its
response to treatment (Chen 2013).
Target condition being diagnosed
Intrahepatic cholestasis of pregnancy is a gestation-specific liver
disorder, defined most often as onset of pruritus, usually from the
third trimester of pregnancy, associated with abnormal liver test
results or raised TSBA, or both, and spontaneous relief after de-
livery in the absence of other skin or liver diseases. Severe intra-
hepatic cholestasis of pregnancy (defined by most authors when
TSBA are greater than 40 µmol/L) (Glantz 2004) seems to be
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associated with an increased proportion of serious adverse fetal
outcomes which include fetal distress, sudden intrauterine death
(possibly due to an acute anoxic event (Sepúlveda 1991) or im-
paired fetal cardiomyocyte function (Williamson 2001)), preterm
labour, meconium staining of amniotic fluid, low birth weight,
or respiratory distress syndrome of the baby (Glantz 2004; Zecca
2006). However, one systematic review restricted to English lan-
guage literature published in 2014 found that the increased risk
for stillbirth, associated most often with intrahepatic cholestasis of
pregnancy, might be questionable because of the scant informa-
tion on how the attributable risk associated with the disease had
been calculated (Henderson 2014).
Clinical suspicion of intrahepatic cholestasis of pregnancy usually
begins from the third trimester with an onset of mild-to-severe
pruritus, frequently generalised on the palms and soles, getting
worse at night and with advancing gestation (Kenyon 2001). In
severe cases, it can also affect the ears, the eyelids, and even the oral
cavity (Reyes 1997). Pruritus in the absence of skin rash, with the
exception of scratching excoriations, could be the only present-
ing symptom of the disease, while constitutional symptoms (in-
somnia, fatigue, anorexia, malaise, or abdominal pain) or typical
cholestatic symptoms (jaundice, malabsorption and vitamin K de-
ficiency, steatorrhoea, pale stools, or dark urine) are rare (Hepburn
2008; Kondrackiene 2008;Mays 2010). Some studies describe in-
stances of pruritus from earlier stages of pregnancy (Brites 1998b;
Keitel 2006; Hubschmann 2016).
Onset of pruritus in late pregnancy usually directs clinicians to
perform liver function tests, and rule out other possible diseases
with serum or urinary markers, and imaging techniques. Despite
the many available tests, an accurate and early diagnosis of intra-
hepatic cholestasis of pregnancy can be difficult, as it shares some
of its clinical features and laboratory findings with other skin dis-
eases (e.g. stretch marks of pregnancy; eczema; pruritic urticar-
ial papules and plaques of pregnancy; infectious, allergic, or im-
munological skin disorders, etc.); liver diseases (e.g. viral and au-
toimmune hepatitis, tumours of hepatobiliary tract, bile stones of
the biliary tree, etc.) (Diken 2014); conditions which may lead to
icterus (e.g. severe hypoglycaemia, some types of encephalopathy,
disseminated intravascular coagulation, etc.); obstetric-specific be-
nign diseases (e.g. pruritus gravidarum, defined as idiopathic on-
set of pruritus during pregnancy but with normal liver tests, or
asymptomatic hypercholanaemia of pregnancy, defined as serum
bile acids level above the upper normal limit without symptoms)
(Castaño 2006); or also more serious diseases (e.g. pre-eclampsia,
haemolysis-elevated liver enzymes-low platelet count syndrome,
or acute fatty liver disease) (Bacq 2011).
Even if most clinicians, in the least suspicion of the disease, initi-
ate an empiric treatment with UDCA, prophylactic vitamin K, or
antihistaminics (or also dexamethasone if pruritus is unbearable),
the diagnosis can only be confirmed when the spontaneous relief
of symptoms and signs after delivery occurs within the usual 48
hours or a few weeks later (two to four weeks), or at most eight
weeks (Geenes 2009). In extremely rare occasions, women may
have symptoms for longer periods of time (Olsson 1993; Aytaç
2006). If the symptoms or signs, related to suspected intrahep-
atic cholestasis of pregnancy, do not disappear within one month,
clinicians should consider other differential diagnosis; and further
investigations are mandatory (Bacq 2011).
Index test(s)
Total serum bile acids
The most frequently used cut-off value of TSBA concentration
for the diagnosis of intrahepatic cholestasis of pregnancy is around
10 µmol/L to 14 µmol/L (Diken 2014). However, there is a vari-
ability in the cut-off values provided in the literature because of
the method of measurement, fasting status, population studied,
or gestational age at diagnosis (Pathak 2010). In addition, an early
finding of normal levels of bile salts during the course of the dis-
ease does not exclude the diagnosis of intrahepatic cholestasis of
pregnancy, and isolated elevation of bile salts in asymptomatic
pregnant women may occur. However, this finding is uncommon
and is most probably asymptomatic hypercholanaemia of preg-
nancy (Castaño 2006). Therefore, the high diagnostic accuracy
attributed to TSBAs for intrahepatic cholestasis of pregnancy is
questionable (Brites 1998a; Diken 2014).
Serum bile acid profile
The serum bile acid profile is composed of concentrations of indi-
vidual primary bile acids (cholic acid (CA) and chenodeoxycholic
acid (CDCA)), secondary bile acids (deoxycholic acid (DCA),
lithocholic acid (LCA), UDCA), and their individual or total
glyco-conjugated (G-c) and T-c forms (Figure 1), including ratios
of some of them (CA/CDCA, total G-c/total T-c), measured in
micromoles per litre. As the measurement of the individual com-
ponents of the serum bile acid profile for the diagnosis of intrahep-
atic cholestasis of pregnancy has never been introduced in clinical
practice, universally accepted cut-off values have not been deter-
mined.
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Figure 1.
The currently available laboratory methods for bile acid analy-
sis are enzyme assay; radioimmunoassay; enzyme immunoassay;
and chromatographicmethods such as thin-layer chromatography,
gas chromatography, high-performance liquid chromatography,
supercritical fluid chromatography, and capillary electrophoresis,
coupled with mass spectrometry, fluorometry, ultraviolet detec-
tion, or electrochemical detection methods. Therefore, we expect
to have heterogeneous results depending on the method used.
Clinical pathway
We describe the current clinical pathway for the diagnosis of intra-
hepatic cholestasis of pregnancy following the ’Green-top Guide-
line no.43’ published by Royal College of Obstetricians and Gy-
naecologists (Green-top Guideline no.43).
Figure 2 presents a schematic overview of the current clinical path-
way.
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Figure 2. Clinical diagnostic pathway for the diagnosis of intrahepatic cholestasis of pregnancy.
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Prior test(s)
Clinical suspicion of intrahepatic cholestasis of pregnancy usually
arises when a woman arrives at a clinical setting claiming onset
of pruritus in the second or third trimester of pregnancy. Initial
examination is to assess the pruritus thoroughly; does it fit within
the description of intrahepatic cholestasis of pregnancy or not?
The clinician should collect data on the woman’s personal and
family history to exclude all other possible causes of pruritus or
a liver disorder, and to identify the possible risk conditions for
infectious diseases or cholestasis. The focus should be on possible
previous known or unknown skin conditions; acute or chronic
liver diseases of any aetiology; pregnancy-specific disorders; family,
personal, and obstetric history; drug history; and travel or meals at
risk of exposure to infective agents. The clinician should determine
if the woman has recently had changes in vision, headache, fever,
abdominal pain, uterine contractions, or if she has noticed dark
urine and pale stool, or vaginal discharges of any type.
Through physical examination, the clinician should be able to
provide further information to rule in or rule out all possible dif-
ferential diagnoses, attesting if any types of rash, icterus, swelling,
hepatosplenomegaly, abdominal pain, uterine contractions, and
hypertension are present. Then, the clinician may strengthen their
diagnostic suspicion by ordering full blood count tests, serum liver
function or liver biochemistry tests, serum pancreatic amylase and
lipase, kidney function tests, or urinary check.
Liver biochemistry or liver function tests are commonly performed
when intrahepatic cholestasis of pregnancy is suspected, but their
normal upper limits in pregnant women are still under discussion
(Mullally 2002). Among the most common liver tests are serum
aminotransferases (altered in up to 60% of women, but with lower
values compared to other aetiologies of liver disease such as viral
hepatitis) (Diken 2014); gamma-glutamyl transpeptidase (raised
in less than one-third of women) (Floreani 2006); alkaline phos-
phatases (not so reliable during pregnancy as its placental synthesis
leads to physiologically increased values (Bacq 1996)); serum or
urinary total, conjugated, and unconjugated bilirubin (raised in
about 25% of women, but with lower values compared to other
cholestatic diseases) (Reyes 1992); and fibrinogen and prothrom-
bin time. Prothrombin levels can be altered with severe liver dys-
function or vitamin K malabsorption due to cholestasis, leading
to an increased risk of postpartum bleeding, but this is very rare in
intrahepatic cholestasis of pregnancy (Reyes 1992). Some women
will have pruritus for days or weeks before the development of ab-
normal liver tests. In pregnant women with persistent unexplained
pruritus, liver tests should be performed every week or two. If clin-
ical evidence and liver tests show a pattern consistent with a viral or
autoimmune aetiology (e.g. high elevation of serum aminotrans-
ferases), further testing is needed (Green-top Guideline no.43).
Ultrasound examination of the liver and biliary tract could help
to rule out other causes of liver disease or of cholestasis, especially
extrahepatic cholestasis (e.g. stones or tumours of the biliary tree)
(Boregowda 2013).
Obstetric examination with ultrasound scans could help to rule
out high-risk conditions of pregnancy or assess the well-being of
the fetus.
There is no ideal method to predict fetal outcome, but a ’non-
stress test’ through cardiotocography and biophysical profile could
provide information about the well-being of the baby at the time
of the investigation (Diken 2014).
Role of index test(s)
The role of an index test, if related to an existent test within a di-
agnostic clinical pathway, can be one of replacement (substitution
of the existent test), triage (addition before the existent test), or
add-on (addition after the existent test).
TSBA is the existing test for the diagnosis of intrahepatic cholesta-
sis of pregnancy. They are usually assessed after the most common
liver tests described above.
CA, glycocholic acid (GCA), CDCA, DCA, LCA, UDCA,
UDCA/LCA ratio, total G-c bile acids, total T-c bile acids, total
G-c bile acids/total T-c bile acid ratio could be considered as add-
on tests after TSBAs. Depending on their diagnostic accuracy, we
may consider any of these as a replacement test or tests of the ex-
istent ones to improve the current clinical pathway.
Alternative test(s)
Alternative tests which can be used to assess intrahepatic cholesta-
sis of pregnancy through exclusion of possible differential diagno-
sis may include serum and urinary biochemical tests, or imaging
techniques.
In case of suspicion of immunological diseases (e.g. primary biliary
cirrhosis, primary sclerosing cholangitis, or other autoimmune dis-
eases), clinicians are advised to test nuclear, smooth muscle, mi-
tochondrial, liver-kidney microsomal autoantibodies, or other or-
gan-specific autoantibodies. In case of suspicion of liver infectious
diseases, clinicians are advised to perform blood serology for the
most common type of hepatotropic viral agents such as hepatitis
A, B, or C viruses; cytomegalovirus; and Epstein-Barr virus.
Among the imaging techniques, if ultrasound does not rule out
other cholestatic diseases, thenmagnetic resonance imaging of the
biliary tree or of the abdomen could be used to exclude possible
causes of extrahepatic cholestasis such as choledochal stones, tu-
mours of the biliary tree, or tumours of the pancreas (Boregowda
2013).
Liver biopsy is indicated only in jaundiced women without pru-
ritus, beginning of symptoms before week 20 of gestation, and
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sustained abnormal laboratory findings beyond eight weeks after
delivery (Boregowda 2013). Liver biopsy is not recommended for
the diagnosis of intrahepatic cholestasis of pregnancy.
We found some biomarker tests which were studied for their accu-
racy in diagnosing intrahepatic cholestasis of pregnancy, but they
weremostly performed in a research setting. Among themwere uri-
nary progesterone metabolites, serum autotaxin activity, and glu-
tathione S-transferase. Urinary progesterone sulphated metabo-
liteswere directly related to the pathogenesis of the disease andwere
studied for the diagnosis of intrahepatic cholestasis of pregnancy
and for monitoring response to treatment (Meng 1997; Reyes
2000b; Abu-Hayyeh 2013). Serum autotaxin activity was shown
to correlate with cholestasis-associated pruritus and was consid-
ered able to distinguish intrahepatic cholestasis of pregnancy from
other pruritic disorders of pregnancy or pregnancy-related liver
diseases (Kremer 2015). Glutathione S-transferase is a detoxifi-
cation liver enzyme with ubiquitous distribution in hepatic cells
and its blood concentration rapidly increases in cases of acute liver
damage (Ozer 2008). Because of this, glutathione S-transferase
could be an earlier andmore accurate indicator of hepatic dysfunc-
tion than liver aminotransferases or total bile acids alone (Dann
2004; Joutsiniemi 2010).
Rationale
Intrahepatic cholestasis of pregnancy is considered a high-risk con-
dition in pregnant women, primarily due to the increased risk of
fetal adverse events. Currently, TSBAs are the most used diagnos-
tic and prognostic markers for the disease, while serum bile acid
profile components are less commonly used. A diagnostic test ac-
curacy systematic review on TSBAs and serum bile acid profile
components has never been published. Thus, assessment of the
accuracy of TSBAs and serum bile acid profile components, inde-
pendently or in combination, and determining which index test
(or combination of index tests) are best, may help us to improve the
current clinical pathway and clinicians’ approaches to the disease,
leading to a direct benefit on the outcomes of pregnant women
and their babies.
Following this, a prognostic accuracy review to assess the reliability
of our index tests also as prognostic markers for the disease could
become feasible.
O B J E C T I V E S
To determine the diagnostic accuracy of total serum bile acids or
total serum bile acids profile, or both for the diagnosis of intrahep-
atic cholestasis of pregnancy in pregnant women presenting with
pruritus.
Secondary objectives
To compare the diagnostic accuracy of total serum bile acids and
each component of serum bile acid profile, considered indepen-
dently or in combination, in diagnosing intrahepatic cholestasis
of pregnancy; to define the optimal cut-off values for these; and
to investigate possible sources of heterogeneity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include prospectively or retrospectively performed diag-
nostic participant-control (case-control) or cross-sectional studies,
irrespective of publication status or language (Colli 2014).
Participants
Pregnant women of any age or ethnicity, recruited in any clinical
setting. They should have undergone the reference standard (see
Reference standards) and any of the index tests, singly or in com-
bination (see Index tests).
Index tests
Wewill consider the following index tests, singly or in combination
(i.e. TSBAs plus any component of serum bile acid profile):
• total serum bile acids (TSBA);
• cholic acid (CA);
• glycocholic acid (GCA);
• chenodeoxycholic acid (CDCA);
• deoxycholic acid (DCA);
• lithocholic acid (LCA);
• ursodeoxycholic acid (UDCA);
• cholic/chenodeoxycholic acid ratio (CA/CDCA);
• total glyco-conjugated bile acids (G-c);
• total tauro-conjugated bile acids (T-c);
• total glyco-conjugated bile acids/total taurine-conjugated
bile acid ratio (G-c/T-c).
Target conditions
Intrahepatic cholestasis of pregnancy defined as pruritus with on-
set during pregnancy associated with abnormal liver tests, both
unexplained by other skin or liver diseases, and which resolves af-
ter delivery (Geenes 2009; Green-top Guideline no.43).
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Reference standards
Clinical evaluation in which follow-up after delivery is included.
In particular, the best reference standard is clinical evaluation con-
sidered as the final judgement of the clinician who takes into ac-
count the whole clinical assessment of signs and symptoms sug-
gestive for intrahepatic cholestasis of pregnancy; the presence of
any otherwise unexplained, persistent abnormalities of aspartate
transaminase (AST), alanine aminotransferase (ALT), or bilirubin
levels until delivery; and follow-up after delivery assessing spon-
taneous relief of symptoms and normalisation of liver tests within
eight weeks at most. We will judge study definitions of the ref-
erence standard to be of lower quality if any of the clinical and
laboratory factors are omitted from the definitions.
Search methods for identification of studies
Electronic searches
We will search The Cochrane Hepato-Biliary Group Controlled
Trials Register (Gluud 2017), The Cochrane Hepato-Biliary
GroupDiagnosticTest of Accuracy StudiesRegister (Gluud 2017),
The Cochrane Pregnancy and Childbirth Group Trials Regis-
ter, The Cochrane Central Register of Controlled Trials (CEN-
TRAL) in The Cochrane Library, MEDLINE (OvidSP), Embase
(OvidSP), Science Citation Index Expanded (SCI-EXPANDED;
Web of Science), CINAHL (EBSCO host), PASCAL, and BIO-
SIS (Web of Science) (Royle 2003).
We will search Chinese literature with the help of Maoling Wei
from the Chinese Cochrane Centre. We will provide details at the
review stage.
As the highest prevalence of the disease is observed in Chile, by
contacting some South American expert authors, we have been
advised to search thoroughly two local databases which are Latino
American and the Caribbean (LILACS) and Scientific Electronic
Library Online (SCIELO).
We will also search through some field-databases suggested by the
Royal College of Obstetricians and Gynaecologists, which are the
Evidence Search: Health and Social Care by NICE, POPLINE,
The World Health Organization (WHO) Reproductive Health
Library (RHL), and The Turning Research into Practice database
(TRIP).
We will apply no language or document-type restrictions.
We have given the preliminary search strategies with the expected
time spans of the searches in Appendix 1.
Searching other resources
We will identify additional references by handsearching the ref-
erences of articles, meta-analyses, and evidence-based guidelines
retrieved from the computerised databases, and the references
suggested by the ’ICP support’ website (www.icpsupport.org/
papers.shtml), to identify other potentially relevant studies for in-
clusion in our review.
We will search for dissertations and theses through ProQuest Dis-
sertations & Thesis Database and Index to Theses in Great Britain
and Ireland, and grey literature throughOpenSIGLE andNational
Technical Information Service (NTIS).
We will search online trial registries such as ClinicalTrial.gov
(clinicaltrials.gov/), European Medicines Agency (EMA) (
www.ema.europa.eu/ema/), WHO International Clinical Trial
Registry Platform (www.who.int/ictrp), the Food and Drug Ad-
ministration (FDA) (www.fda.gov), and pharmaceutical company
sources as well as contacting experts in the field for ongoing or
unpublished trials.
Data collection and analysis
We will follow the guidelines provided in the Cochrane Handbook
for Systematic Reviews of Diagnostic Test Accuracy (Macaskill 2010).
Selection of studies
Two review authors (CM, TS) will independently conduct the
first selection of studies by reading titles or abstracts, or both, of
the identified studies. The two review authors will independently
review the full texts for eligibility, assessing the fulfilment of the
inclusion criteria. During this second selection stage, if the two
review authors find multiple publications of one study fulfilling
the inclusion criteria, they will group them together and they will
screen these publications for complimentary data or check them
for discrepancies. If in doubt, the review authors will write e-mails
to study authors to ensure that publications refer to the same study
and to check the correctness of data. During this process, the two
authors will classify study references as either Included studies or
Excluded studies, completing also the Characteristics of included
studies and Characteristics of excluded studies.
We will solve disagreements by discussion or by consulting a third
review author (CG, GC, or DN).
Data extraction and management
Two review authors (CN,TS)will independently extract data from
each included study. They will solve disagreements by discussion
or by consulting a third review author (CG, GC, or DN).
They will retrieve the following study data:
• general information: title, journal, year, publication status,
study design (cross-sectional or participant-control, prospective
or retrospective, single centre or multicentre), time span;
• total number of women screened for inclusion, number of
pregnant women included, and prevalence of the disease in the
considered population;
• baseline characteristics: age, ethnicity, country, if
pregnancies were multiple or single, week of pregnancy in which
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the index tests were performed, disease severity, and concurrent
medications used;
• if most common liver tests were performed, and their
findings;
• index tests (TSBAs or any component of serum bile acid
profile): technique used for the measurement, fasting or
postprandial status of women when the test was performed, and
predefined cut-off values for the diagnosis;
• follow-up after delivery: length of follow-up, length of time
needed for assessment of the spontaneous relief of symptoms,
and normalisation of liver tests;
• number of true positive (TP), true negative (TN), false
positive (FP), and false negative (FN) results comparing index
test results with reference standard;
• information related to the QUADAS-2 items for evaluation
of the risk of bias of the studies (Whiting 2011).
The two review authors will summarise data from each study in
two by two tables (FP, FN, TP, TN) and will enter the data into
Review Manager 5 (RevMan 2014).
Missing data
If information on any of the FP, FN, TP, or TN diagnostic test
values are missing, we will attempt to contact the authors of the
included studies to obtain missing information. We will also con-
tact authors if other types of information needed for this review
are missing, especially when the publication is an abstract or poster
presentation. We will use Excel and ReviewManager 5 to add data
required for statistical analyses (RevMan 2014).
We will contact primary authors for missing data by e-mail. In the
absence of a reply, wewill send a second e-mail oneweek later, orwe
will contact the study authors by telephone. We will acknowledge
study authors for providing missing data, and we will create refer-
ences to unpublished studies following theCochrane StyleManual
(community.cochrane.org/book˙pdf/224) when such study data
are obtained through personal communication.
We will exclude the studies if we cannot obtain the data needed
for the two by two tables.
Assessment of methodological quality
Design flaws in test accuracy studies can produce biased results
(Lijmer 1999; Whiting 2004; Rutjes 2006). In addition, evalua-
tion of study results is quite often impossible due to incomplete
reporting (Smidt 2005).
To limit the influence of different biases, two review authors will
independently assess the risk of bias of the included studies using
QUADAS-2 domains (Whiting 2011). A third review author will
check the extractionof data concerning the assessment of the risk of
bias.Wewill resolve disagreements by discussion or by consulting a
fourth review author.We will contact study authors if information
on methodology is lacking in order to assess correctly the risk of
bias of the studies.
We will adopt the domains in Appendix 2 to address aspects of
study quality involving the participant spectrum, index test, ref-
erence standard, and flow and timing. We will classify a study at
low risk of bias only if classified at ’low risk of bias’ in all the four
domains (participant spectrum, index test, reference standard, and
flow and timing); otherwise, we will consider the study at high
risk of bias (Jüni 1999; Whiting 2005).
We will use tabular and graphical displays to summarise
QUADAS-2 assessments.
Statistical analysis and data synthesis
We will carry out the analyses following Chapter 10 of the
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accu-
racy (Macaskill 2010).We will use the ReviewManager 5 software
for analyses and forest plots (RevMan 2014).
We will build two by two tables for each primary study and for all
the index tests considered. We will estimate sensitivity, specificity,
and positive and negative likelihood ratios (LR+ and LR-) with
their 95% confidence intervals (CI). We plan to present data in
coupled forest plots, showing sensitivities and specificities of each
study, with their 95%CI.We plan to plot the studies in the receiver
operator characteristic (ROC) space, reporting sensitivity against
1 - specificity.
If included studies show very heterogeneous results or are at high
risk of bias, we might not perform meta-analyses, or, if we decide
to conduct such meta-analyses, then we will be cautious with in-
terpretation of the results.
If the included primary studies report accuracy data using differ-
ent cut-off values, we will adopt the hierarchical summary ROC
model (HSROC) to pool data and to estimate a summary ROC
(SROC) curve. If a sufficient number of primary studies report
data using common cut-off values, we will perform meta-analyses
using the bivariate model and we will provide the estimate of the
summary operating point (the point with mean sensitivity and
mean specificity) at those cut-off values.
For primary studies which reported accuracy results for more than
one cut-off point, wewill report sensitivities and specificities for all
the cut-off points.Wewill include only one cut-off point (themost
commonly reported) when we perform the HSROC analysis. On
the contrary, we will include all the relevant cut-off points when
we perform the bivariate analysis considering the studies which
share a common cut-off value.
We will make direct and indirect comparisons of the considered
index tests by adding the index tests as covariates to the bivariate
or HSROC model.
We will use SAS statistical software, release 9.4 (SAS Institute Inc.,
Cary, NC, USA) to perform all statistical analyses.
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Investigations of heterogeneity
We will investigate heterogeneity first by visual inspection of the
paired forest plots of sensitivities and specificities for each index
test. Subsequently, we will perform a formal analysis, where ap-
propriate, by adding covariates to the bivariate or HSROCmodel.
Wewill consider the following as possible sources of heterogeneity:
• country in which the study took place;
• participant selection: studies including only pregnant
women with suspicion of intrahepatic cholestasis of pregnancy
versus studies including all pregnant women;
• laboratory techniques used for the measurement of the
index tests;
• participant treatment with UDCA versus no treatment;
• fasting or postprandial status of pregnant women at the
time when the serum samples were taken;
• timing of assessment of the index test(s): the time when the
symptoms arose, the peak values among multiple assessments
during pregnancy, immediately before delivery;
• differences in study definitions of intrahepatic cholestasis of
pregnancy.
Sensitivity analyses
We will perform sensitivity analyses by excluding studies at high
risk of bias (studies judged as high risk of bias or unclear risk of
bias in at least one of the domains of QUADAS-2) to explore the
influence of the quality of the included studies.
Then, we will perform different sensitivity analyses as follows:
• excluding all studies with participant-control (case-control)
design;
• excluding only studies with participant-control design
which enrolled as controls asymptomatic pregnant women (i.e.
without symptoms suggestive for cholestasis);
• excluding studies in which the index test was part of the
reference standard.
If the planned sensitivity analyses show robustness of the main
analysis, we will use the results of the main analysis for drawing
conclusions. Otherwise, in case of discrepancies between the re-
sults of the main and the sensitivity analyses, we will use the re-
sults of the sensitivity analysis (only studies at low risk of bias) for
drawing conclusions.
Assessment of reporting bias
Wewill produce a funnel plot to investigate reporting bias visually,
using the statistical method suggested by Deeks and colleagues
(Deeks 2005).
’Summary of findings’ table
To construct a ’Summary of findings’ table for presenting the key
findings of our review, we will use the approach developed by The
Cochrane GRADEing group (formerly, The Cochrane Applica-
bility and Recommendations Methods Group) which is in confor-
mity with theQUADAS-2 (see Chapter 11 of theCochrane Hand-
book for Systematic Reviews of Diagnostic Test Accuracy, Whiting
2011; Bossuyt 2013). Thus, in our ’Summary of findings’ table,
we will include key information on the review question and its
components (population, setting, index tests, role and purpose of
tests, and reference standard), providing accuracy estimates, the
available data (number of participants and studies), quality of the
included studies, and the practical implications of the results (by
providing prevalence estimates and calculating women with FP
and FN results in a cohort of 1000 women with suspected in-
trahepatic cholestasis of pregnancy). The quality of evidence in a
’Summary of findings’ table refers to the degree to which study
methods avoided risk of bias in estimates of diagnostic accuracy
and the extent to which primary studies are applicable to the re-
search question (The Cochrane GRADEing group). To make a
judgement on how reliable summary estimates are, we will indi-
cate if studies are at high risk of bias: where studies are at high risk
of bias, we will recommend cautious application of the results of
our review in clinical practice.
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A P P E N D I C E S
Appendix 1. Preliminary search strategies
Database Time span Preliminary search strategies
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
Date will be given at review stage. (((bile or cholic or glycocholic or chenodeox*cholic
or deox*cholic or lithocholic or ursodeox*cholic or
glyco-conjugated or tauro-conjugated or glycine or
taurine) and acid*) or (chol*glycine or TSBA orCA
or GCA or CDCA or LCA or DCA or UDCA))
AND ((cholesta* and (hepat* or liver*)) or jaun-
dice or (icterus gravidarum)) AND (pregnan* or
obstetric* or gestation*)
The Cochrane Pregnancy and Childbirth
Group Trials Register
Date will be given at review stage. (((bile or cholic or glycocholic or chenodeox*cholic
or deox*cholic or lithocholic or ursodeox*cholic or
glyco-conjugated or tauro-conjugated or glycine or
14Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
taurine) and acid*) or (chol*glycine or TSBA orCA
or GCA or CDCA or LCA or DCA or UDCA))
AND ((cholesta* and (hepat* or liver*)) or jaun-
dice or (icterus gravidarum)) AND (pregnan* or
obstetric* or gestation*)
The Cochrane Hepato-Biliary Group Di-
agnostic Test of Accuracy Studies Register
Date will be given at review stage. (((bile or cholic or glycocholic or chenodeox*cholic
or deox*cholic or lithocholic or ursodeox*cholic or
glyco-conjugated or tauro-conjugated or glycine or
taurine) and acid*) or (chol*glycine or TSBA orCA
or GCA or CDCA or LCA or DCA or UDCA))
AND ((cholesta* and (hepat* or liver*)) or (jaun-
dice or (icterus gravidarum)) AND (pregnan* or
obstetric* or gestation*)
The Cochrane Central
Register of Controlled Trials (CENTRAL)
in The Cochrane Library
Latest issue #1MeSH descriptor: [Bile Acids and Salts] explode
all trees
#2 ((bile or cholic or glycocholic or chen-
odeox*cholic or deox*cholic or lithocholic or ur-
sodeox*cholic or glyco-conjugated or tauro-con-
jugated or glycine or taurine) and acid*) or
(chol*glycine or TSBA or CA or GCA or CDCA
or LCA or DCA or UDCA)
#3 #1 or #2
#4 MeSH descriptor: [Cholestasis, Intrahepatic]
explode all trees
#5 (cholesta* and (hepat* or liver*)) or jaundice or
(icterus gravidarum)
#6 #4 or #5
#7 MeSH descriptor: [Pregnancy] explode all trees
#8 pregnan* or obstetric* or gestation*
#9 #7 or #8
#10 #3 and #6 and #9
MEDLINE (OvidSP) 1946 to the date of search 1. exp “Bile Acids and Salts”/
2. ((bile or cholic or glycocholic or chen-
odeox*cholic or deox*cholic or lithocholic or
ursodeox*cholic or glyco-conjugated or tauro-
conjugated or glycine or taurine) and acid* or
(chol*glycine or TSBA or CA or GCA or CDCA
or LCA or DCA or UDCA)).mp. [mp=title, ab-
stract, original title, name of substance word, sub-
ject heading word, keyword heading word, proto-
col supplementary concept word, rare disease sup-
plementary concept word, unique identifier]
3. 1 or 2
4. exp Cholestasis, Intrahepatic/
5. ((cholesta* and (hepat* or liver*)) or jaundice or
icterus gravidarum).mp. [mp=title, abstract, orig-
15Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
inal title, name of substance word, subject head-
ing word, keyword heading word, protocol supple-
mentary concept word, rare disease supplementary
concept word, unique identifier]
6. 4 or 5
7. exp Pregnancy/
8. (pregnan* or obstetric* or gestation*).mp. [mp=
title, abstract, original title, name of substance
word, subject heading word, keyword heading
word, protocol supplementary concept word, rare
disease supplementary concept word, unique iden-
tifier]
9. 7 or 8
10. 3 and 6 and 9
Embase (OvidSP) 1974 to the date of search 1. exp bile acid/
2. (((bile or cholic or glycocholic or chen-
odeox*cholic or deox*cholic or lithocholic or ur-
sodeox*cholic or glyco-conjugated or tauro-con-
jugated or glycine or taurine) and acid*) or
(chol*glycine or TSBA or CA or GCA or CDCA or
LCA or DCA or UDCA)).mp. [mp=title, abstract,
heading word, drug trade name, original title, de-
vice manufacturer, drugmanufacturer, device trade
name, keyword]
3. 1 or 2
4. exp intrahepatic cholestasis/
5. ((cholesta* and (hepat* or liver*)) or jaundice
or (icterus gravidarum)).mp. [mp=title, abstract,
heading word, drug trade name, original title, de-
vice manufacturer, drugmanufacturer, device trade
name, keyword]
6. 4 or 5
7. exp pregnancy/
8. (pregnan* or obstetric* or gestation*).mp. [mp=
title, abstract, headingword, drug trade name, orig-
inal title, device manufacturer, drug manufacturer,
device trade name, keyword]
9. 7 or 8
10. 3 and 6 and 9
Science Citation Index Expanded (Web of
Science)
1900 to the date of search #4 #1 AND #2 AND #3
#3 TS=(pregnan* or obstetric* or gestation*)
#2 TS=((cholesta* and (hepat* or liver*)) or jaun-
dice or (icterus gravidarum))
#1 TS=((bile or cholic or glycocholic or chen-
odeox*cholic or deox*cholic or lithocholic or ur-
sodeox*cholic or glyco-conjugated or tauro-con-
jugated or glycine or taurine) and acid*) or
16Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
(chol*glycine or CA or GCA or CDCA or LCA or
DCA or UDCA))
CINAHL (EBSCO host) 1981 to the date of search. S10 S6 AND S9
S9 S8 OR S7
S8 TX pregnan* or obstetric* or gestation*
S7 MW Pregnancy
S6 S4 OR S5
S5TX (cholesta* and (hepat* or liver*)) or jaundice
or (icterus gravidarum)
S4 MW Intrahepatic Cholestasis
S3 S1 OR S2
S2 TX ((bile or cholic or glycocholic or chenodeox?
cholic or deox?cholic or lithocholic or ursodeox?
cholic or glyco-conjugated or tauro-conjugated or
glycine or taurine) and acid?) or (chol?glycine or
TSBA or CA or GCA or CDCA or LCA or DCA
or UDCA)
S1 MW Bile Acids and Salts
BIOSIS Previews (Web of Science) 1969 to the date of search #4 #1 AND #2 AND #3
#3 TS=(pregnan* or obstetric* or gestation*)
#2 TS=((cholesta* and (hepat* or liver*)) or jaun-
dice or (icterus gravidarum))
#1 TS=(((bile or cholic or glycocholic or chen-
odeox*cholic or deox*cholic or lithocholic or ur-
sodeox*cholic or glyco-conjugated or tauro-con-
jugated or glycine or taurine) and acid*) or
(chol*glycine or TSBA or CA or GCA or CDCA
or LCA or DCA or UDCA))
LILACS (VHL) Date will be given at review stage. 1. (tw:((tw:(cholestasis )) AND (tw:(pregnancy
OR obstetric)))) OR (tw:((tw:( colestasis)) AND
(tw:(gravídica OR (intrahepática AND embarazo)
OR obstétrica)))) OR (tw:((tw:(ictericia)) AND
(tw:(embarazo OR gravídica)))) OR (tw:((tw:
(colestase)) AND(tw:(gravidezORgestacionalOR
obstétrica)))) OR (tw:( (tw:(icterícia)) AND (tw:
(gravidez OR colestática)))) AND (instance:“re-
gional”) AND ( db:(“LILACS”))
2. (tw:(acidos biliares)) AND (tw:(embarazo OR
gravidez OR obstétrica OR gestational OR gra-
vidica)) AND (instance:“regional”) AND ( db:
(“LILACS”))
3. (((mh:(“Bile Acids and Salts”)) OR (tw:(aci-
dos biliares))) AND ((mh:(“Cholestasis, Intra-
hepatic”)) OR (tw:(cholestasis OR colestasis OR
colestase OR ictericia))) AND ((mh:(“Pregnancy
Complications”)) OR (tw:(pregnancy OR obstet-
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ric OR gravídica OR embarazo OR obstétrica OR
gravidez OR gestacional)))) AND (instance:“re-
gional”) AND (db:(“LILACS”))
SCIELO Date will be given at review stage. 1. ((cholestasis) AND (pregnancy OR obstetric) )
OR ((colestasis) AND (embarazo OR obstétrica)
) OR ((ictericia) AND (embarazo OR gravídica)
) OR ( (icterícia) AND (gravidez OR colestática))
OR ((colestase) AND (gravidez OR gestacional) )
2. (bile acids) AND (pregnancy OR obstetric)
3. (acidos biliares) AND (embarazo OR gravidez
OR obstétrica OR gestational OR gravidica)
4. ((cholestasis) AND (pregnancy OR obstetric) )
OR ((colestasis) AND (embarazo OR obstétrica)
) OR ((ictericia) AND (embarazo OR gravídica)
) OR ((icterícia) AND (gravidez OR colestática))
OR ((colestase) AND (gravidez OR gestacional) )
OR ((bile acids) AND (pregnancy OR obstetric))
OR ((acidos biliares) AND (embarazoOR gravidez
OR obstétrica OR gestational OR gravidica))
TRIP, RHL, Evidence search: Health and
Social Care, OpenSIGLE, NTIS
Date will be given at review stage. 1. cholestasis AND (obstetric OR pregnancy OR
pregnant OR gestation OR gestational)
2. (obstetric OR pregnancy OR pregnant OR ges-
tation OR gestational) AND ((bile acid) OR (bile
acids) OR (bile salt) OR (bile salts))
3. cholestasis AND (obstetric OR pregnancy OR
pregnantORgestationORgestational) AND((bile
acid) OR (bile acids) OR (bile salt) OR (bile salts)
)
4. (icterus OR jaundice OR pruritus) AND (gravi-
darum OR pregnancy OR obstetric)
5. (cholestasis OR (bile acid) OR (bile acids) OR
(bile salt) OR (bile salts)) AND (obstetric OR
pregnancy OR pregnant OR gestation OR gesta-
tional) OR ((icterus OR jaundice OR pruritus)
AND (gravidarum OR pregnancy OR obstetric))
Chinese databases (CNKI, VIP) Date will be given at review stage. Search strategies in Chinese can be obtained by
contacting the first review author, CM
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Appendix 2. QUADAS-2
Domain Participant selection Index test Reference standard Flow and timing
Description Describe
methods of participant
selection: describe in-
clusion criteria for par-
ticipants (prior testing,
presentation, intended
use of index test, and
setting):
The studies that fulfil the
inclusion criteria of this
review should have in-
cluded pregnant women
recruited in any clinical
setting
They should have been
evaluated for personal
history of skin or liver
diseases, presence of pru-
ritus during their preg-
nancy, and been as-
sessed with any of the
most common liver test
(or tests), followed by
any of the already men-
tioned index tests (to-
tal bile acids, cholic
acid, glycocholic acid,
chenodeoxycholic acid,
deoxycholic acid, litho-
cholic acid, ursodeoxy-
cholic acid, cholic/chen-
odeoxycholic acids, to-
tal glyco-conjugated bile
acids, total tauro-con-
jugated bile acids, to-
tal glyco-conjugated bile
acids/total taurine-con-
jugated bile acids)
Describe the index test
and how it was con-
ducted and interpreted:
The index tests (total
bile acids, cholic acid,
glycocholic acid, chen-
odeoxycholic acid, de-
oxycholic acid, litho-
cholic acid, ursodeoxy-
cholic acid, cholic/chen-
odeoxycholic acids, to-
tal glyco-conjugated bile
acids, total tauro-con-
jugated bile acids, to-
tal glyco-conjugated bile
acids/total taurine-con-
jugated bile acids) are
non-invasive laboratory
serum tests performed
after the first clinical
evaluation of the preg-
nant women for the
diagnosis of intrahep-
atic cholestasis of preg-
nancy. The serum con-
centration of the in-
dex test(s) can be as-
sessed through different
techniques. Laboratory
methods and diagnostic
cut-off values could vary
between studies
Describe the reference
standard and how it
was conducted and in-
terpreted:
Clinical evaluation in-
cluding follow-up af-
ter delivery. The clini-
cal evaluation is the final
judgement of the clini-
cian who takes into ac-
count the clinical assess-
ment of suggestive signs
and symptoms for in-
trahepatic cholestasis of
pregnancy and the pres-
ence of any otherwise
unexplained, persistent
abnormalities of aspar-
tate transaminase, ala-
nine amino-
transferase, or bilirubin
levels until delivery. The
follow-up after delivery
is the assessment of spon-
taneous relief of symp-
toms and normalisation
of liver tests within 8
weeks at most
Describe any people
who did not receive the
index test(s) or refer-
ence standard (or both)
or who will be excluded
from the 2 ×2 table (re-
fer to flow diagram):
describe the time in-
terval and any inter-
ventions between in-
dex test(s) and refer-
ence standard:
Pregnant women consid-
ered for inclusion should
have undergone the ref-
erence standard and any
of the index tests, singly
or in combination (see
Reference standards,
Index tests and clinical
diagnostic pathway rep-
resented in Figure 2).We
will exclude participants
who lack data for the 2 ×
2 table
To define a time inter-
val between our index
tests and our reference
standard is not relevant,
as the index tests should
be performed when the
suspicion of intrahepatic
cholestasis of pregnancy
arises and the reference
standard comprises the
follow-up after delivery
Signalling questions:
yes/no/unclear
Was a consecutive or
random sample of par-
ticipants enrolled?
Yes: all consecutive par-
ticipants or random sam-
ple of people with sus-
pected in-
Were the index test re-
sults interpreted with-
out knowledge of the
results of the reference
standard?
Yes: the index test results
were interpreted without
Is the reference stan-
dard likely to clas-
sify the target condi-
tion correctly?
Yes: if participants un-
derwent a thorough clin-
ical evaluation excluding
Was there an appropri-
ate interval between in-
dex test(s) and refer-
ence standard?
This is not a relevant
question to our review.
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trahepatic cholestasis of
pregnancy were enrolled
in the study
No: selected participants
were not included.
Unclear: insuffi-
cient data were reported
to permit a judgement
knowledge of the results
of the reference standard
No: the index test re-
sults were not inter-
preted without knowl-
edge of the results of the
reference standard
Unclear: insuffi-
cient data were reported
to permit a judgement
all possible differential
diagnoses and if they un-
derwent an adequate fol-
low-up after delivery as-
sessing the spontaneous
relief of symptoms and
normalisation of the pre-
viously found abnormal
liver tests
No: clinical evaluation
including the follow-up
after delivery was not
able to rule out other
possible differential di-
agnosis
Unclear: insuffi-
cient data were reported
to permit a judgement
Was a participant-con-
trol design avoided?
Yes: participant-control
design was avoided.
No: participant-control
design was not avoided.
Unclear: insufficient in-
formation was reported
to permit a judgement
If a threshold was used,
was it prespecified?
Yes: the threshold was
prespecified.
No: the threshold was
not prespecified.
Unclear: it was not re-
ported or not clearly de-
scribed.
Were the reference
standard results inter-
preted without knowl-
edge of the results of
the index test?
Yes: clinical evaluation
including the follow-up
after delivery was per-
formed without knowl-
edge of the results of TS-
BAs or any component
of serum bile acid profile
No: clinical evaluation
including the follow-up
after delivery was per-
formed with knowledge
of the results ofTSBAs or
any component of serum
bile acid profile
Unclear: insuffi-
cient data were reported
to permit a judgement
Did all participants re-
ceive the reference stan-
dard?
Yes: all partici-
pants underwent the ref-
erence standard, i.e. clin-
ical evaluation including
the follow-up after deliv-
ery
No: not all participants
underwent the reference
standard, i.e. clinical
evaluation including the
follow-up after delivery
Unclear: insuffi-
cient data were reported
to permit a judgement
Did the study avoid in-
appropriate
exclusions?
Yes: the study avoided
inappropriate exclusions
(e.g. women having a
previously assessed value
Was the index test eval-
uation not part of the
reference standard?
Yes: the index test evalu-
ation was not part of the
reference standard
Did all participants re-
ceive the same reference
standard?
Yes: all participants re-
ceived the same refer-
ence standard (i.e. clini-
20Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
of the index test(s) below
a defined cut-off )
No: the study excluded
participants inappropri-
ately.
Unclear: insuffi-
cient data were reported
to permit a judgement
No: index test evaluation
was part of the reference
standard
Unclear: insuffi-
cient data were reported
to permit a judgement
cal evaluation including
the follow-up after deliv-
ery)
No: not all participants
received the same refer-
ence standard (i.e. clini-
cal evaluation including
the follow-up after deliv-
ery)
Unclear: insuffi-
cient data were reported
to permit a judgement
Were all participants
included in the analy-
sis?
Yes: all participants
meeting the selection cri-
teriawere included in the
analysis, or data on all
the selected participants
were available so that a 2
× 2 table including all se-
lected participants could
be constructed
No: not all participants
meeting the selection cri-
teriawere included in the
analysis or the 2 × 2 table
could not be constructed
using data on all selected
participants
Unclear: insuffi-
cient data were reported
to permit a judgement
Risk of bias: high/low/
unclear
Could the selection of
participants have intro-
duced bias?
High risk of bias: yes, if
the selection of partici-
pants introduced bias
Low risk of bias: no,
if the selection of par-
ticipants had not intro-
duced bias
Unclear risk of bias: in-
sufficient data were re-
Could the conduct or
interpretation of the
index test have intro-
duced bias?
High risk of bias: if the
answer to the signalling
questions on the conduct
or interpretation of the
index test was ’no’
Low risk of bias: if the
answer to the signalling
questions on the conduct
Could
the reference standard,
its conduct, or its in-
terpretation have intro-
duced bias?
High risk of bias: if the
answer to the signalling
questions on the refer-
ence standard, its con-
duct, or its interpreta-
tion was ’no’
Low risk of bias: if the
Could the participant
flow have introduced
bias?
High risk of bias: if the
answer to the signalling
questions on flow and
timing was ’no’
Low risk of bias: if the
answer to the signalling
questions on flow and
timing was ’yes’
Unclear risk of bias: if
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ported to permit a judge-
ment on the risk of bias
or interpretation of the
index test was ’yes’
Unclear risk of bias: if
the answers to the 2
signalling questions on
the conduct or interpre-
tation of the index test
were either ’unclear’ or
any combination of ’un-
clear’ with ’yes’ or ’no’
answer to the signalling
questions on the refer-
ence standard, its con-
duct, or its interpreta-
tion was ’yes’
Unclear risk of bias: if
the answers to the 3
signalling questions on
the reference standard,
its conduct, or its in-
terpretation were either
’unclear’ or any combi-
nation of ’unclear’ with
’yes’ or ’no’
the answers to the 4 sig-
nalling questions on flow
and timing were either
’unclear’ or any combi-
nation of ’unclear’ with
’yes’ or ’no’
Concerns regard-
ing applicability: high/
low/unclear
Are there concerns that
the included partici-
pants do not match the
review question?
High concern: there was
high concern that the in-
cluded participants did
not match the review
question
Low concern: there was
low concern that the in-
cluded participants did
not match the review
question
Unclear concern: if it was
unclear.
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
High concern: there was
high concern that the
conduct or interpreta-
tion of TSBAs or any
component of serumbile
acid profile differed from
the way likely to be used
in clinical practice
Low concern: there was
low concern that the
conduct or interpreta-
tion of TSBAs or any
component of serumbile
acid profile differed from
the way likely to be used
in clinical practice
Unclear concern: if it was
unclear.
Are there concerns that
the target condition as
defined by the refer-
ence standard does not
match the review ques-
tion?
High concern: all par-
ticipants did not un-
dergo clinical evaluation
including the follow-up
after delivery
Low concern: all partici-
pants underwent clinical
evaluation including the
follow-up after delivery
Unclear concern: if it was
unclear.
-
TSBA: total serum bile acid.
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